SCHEMBL17708483

SCHEMBL17708483

O=C(Nc1nc2ccccc2s1)c1ccc(N(Cc2ccc(F)cc2)C(=O)[C@H]2O[C@@H]2C(=O)Nc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 5/20 0.56
▸ MMP13 P45452 2/20 0.56
▸ NPC1 O15118 7/20 0.50
▸ RAB9A P51151 7/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ NFKB2 Q00653 1/20 0.50
▸ RELA Q04206 1/20 0.50
▸ ABL1 P00519 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16276192 0.93 NPC1 (0.57) SCDMMP13NPC1RAB9AKDM4E
SCHEMBL16276348 0.90 NPC1 (0.53) SCDMMP13NPC1RAB9AKDM4E
SCHEMBL16276301 0.88 NPC1 (0.55) SCDNPC1RAB9AKDM4ENFKB1
SCHEMBL16276155 0.88 NPC1 (0.52) SCDMMP13NPC1RAB9AKDM4E
SCHEMBL16276196 0.87 NPC1 (0.53) SCDMMP13NPC1RAB9AKDM4E
SCHEMBL17708494 0.86 NPC1 (0.51) SCDNPC1RAB9AKDM4ENFKB1
SCHEMBL16276157 0.85 NPC1 (0.51) SCDMMP13NPC1RAB9AKDM4E
SCHEMBL16276105 0.85 NPC1 (0.51) SCDNPC1RAB9AKDM4ENFKB1
SCHEMBL16276111 0.85 NPC1 (0.60) SCDMMP13NPC1RAB9AKDM4E
SCHEMBL17708488 0.84 KDM4E (0.53) SCDNPC1RAB9AKDM4ENFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630957-B2 2,3-butanediamide epoxide compound and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 — — US disclosed
US-20160115160-A1 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2016-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115160-A1 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof ECE2, GNE, EPHX2 SCD 552/4885MMP13 2548/4885NPC1 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback